




The relative strengths and weaknesses of Lyell Immunopharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lyell Immunopharma Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 119% points. The greatest weakness of Lyell Immunopharma Inc is the variable Research and Development, reducing the Economic Capital Ratio by 28% points.

The company's Economic Capital Ratio, given in the ranking table, is 278%, being 63% points above the market average of 215%.

Input Variable	Value in 1000 USD
Assets, Current	379,594
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	53,788
Liabilities, Non-Current	54,247
Other Assets	63,065
Other Compr. Net Income	385
Other Expenses	47,988
Other Liabilities	0
Other Net Income	15,761
Other Revenues	61
Property and Equipment	48,200
Research and Development	258,787
Selling, General and Administrative Expense	52,041

Output Variable	Value in 1000 USD
Assets	490,859
Liabilities	108,035
Expenses	358,816
Revenues	61
Stockholders Equity	382,824
Net Income	-342,994
Comprehensive Net Income	-342,802
BaseVar	486,958
ECR before LimitedLiability	164%
Economic Capital Ratio	278%